{"id":"NCT05194540","sponsor":"LEO Pharma","briefTitle":"Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)","officialTitle":"An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-13","primaryCompletion":"2023-06-06","completion":"2023-06-21","firstPosted":"2022-01-18","resultsPosted":"2024-06-20","lastUpdate":"2025-03-11"},"enrollment":136,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Tralokinumab","otherNames":[]}],"arms":[{"label":"Tralokinumab subcutaneous dosing by an autoinjector","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).","primaryOutcome":{"measure":"Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Tralokinumab Subcutaneous Dosing by an Autoinjector","deltaMin":28.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":29,"countries":["United States"]},"refs":{"pmids":["40681936"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":136},"commonTop":["Injection site reaction","Dermatitis atopic","Conjunctivitis","Injection site pain","COVID-19"]}}